[Treatment of Parkinson disease].
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects; D004359:Drug Therapy, Combination; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy; D011725:Pyridines / Q000009:adverse effects; D011954:Receptors, Dopamine / Q000187:drug effects
D000978:Antiparkinson Agents; D011725:Pyridines; D011954:Receptors, Dopamine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Zur Behandlung der Parkinson-Krankheit.